The purpose of the study is to see how a dietary oil called conjugated linoleic acid, or CLA, might be useful in combination with diabetes medication. Some studies show that CLA can modestly reduce body weight and body fat. Our research idea is that taking CLA will reduce body weight and body fat without interfering with the diabetes medications' effects on blood sugar.
The long term goal of this research is to develop effective complementary strategies to aid in the management of type 2 diabetes (T2DM). Our central hypothesis is that CLA reduces body weight and body fat mass when administered concomitantly with oral diabetes medication, The rationale of this study is that using CLA to reduce body weight and body fat in people with T2DM may improve efficacy and longevity of the oral diabetes medications in the management of T2DM. We plan to test our central hypothesis and accomplish the overall objective of this research by pursuing the following three specific aims. Specific Aim 1: Determine the ability of CLA to reduce body weight and body fat mass in people using oral diabetes medication for management of T2DM. Specific Aim 2: Determine the ability of CLA to modulate insulin sensitivity when combined with oral diabetes medication. Specific Aim 3: Determine the safety and tolerability of CLA in combination with oral diabetes medication.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
48
Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
3.2 g/day, capsule, week 0 to week 32
6.4 g/day, capsule, week 0 to week 32
The Ohio State University Clinical Research Center (Davis Medical Research Center)
Columbus, Ohio, United States
Difference in change in body weight of the intervention groups
Time frame: Between baseline and week 32, or end of study
Change in fat mass
Time frame: Between baseline and week 32
Change in lean mass
Time frame: Between baseline and week 32
Change in insulin sensitivity
Time frame: Between week 0 and week 32
Change in lipid profile (TChol, LDL, HDL, C-reactive protein)
Time frame: Weeks -4, -1, 0, 8, 16, 24, 31, 32
Changes in adipocytokine profile (leptin, adiponectin, visfatin, and resistin)
Time frame: Weeks -4, -1, 0, 8, 16, 24, 31, 32
Changes in liver enzymes (ALT and AST)
Time frame: Weeks -4, -1, 0, 8, 16, 24, 31, 32
Edema
Time frame: Weeks -4, -1, 0, 8, 16, 24, 31, 32
Change in glucose control
Time frame: Weeks -1, 16, 31
Change in bone density, bone formation and resorption markers
Time frame: Weeks -4, -1, 31
Change in C-Peptide
Time frame: Weeks - 4, -1, 0, 1, 8, 16, 24, 31, 32
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Diabetes coping behaviors and self-efficacy
Time frame: Weeks -4, -1, 32
Chronic stress (as measured by questionnaire)
Time frame: Weeks -4 and 32
Appetite (as measured by appetite rating scale)
Time frame: Weeks -4, 0, 16, 32
EKG
Time frame: Weeks -4, 16, 32
BNP (brain type natriuretic peptide)
Time frame: Weeks -4 and 32
Energy balance (physical activity recalls, food records, indirect calorimetry)
Time frame: Weeks -1, 16, 31
Compliance (fatty acid composition, pill counts)
Time frame: Weeks -1, 0, 8, 16, 24, 31, 32
Nutrition knowledge
Time frame: Weeks -4, 0, 32